You are here

An innovative in situ cell reprogramming technology for cancer treatment

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41CA183103-01
Agency Tracking Number: R41CA183103
Amount: $225,000.00
Phase: Phase I
Program: STTR
Solicitation Topic Code: NCI
Solicitation Number: PA13-089
Solicitation Year: 2014
Award Year: 2014
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
TROY, MI 48098-7100
United States
DUNS: 78684788
HUBZone Owned: No
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (313) 916-7564
Business Contact
Phone: (248) 824-6829
Research Institution
RESEARCH ADMINISTRATION CFP046 2799 West Grand Boulevard
DETROIT, MI 48202-2689
United States

 () -
 Domestic Nonprofit Research Organization

DESCRIPTION (provided by applicant): We invented an innovative protein induced Pluripotent Stem Cells (piPSCs) technology that generates piPSCs from normal fibroblast and cancer cells within 1-week with 90 4% conversion efficiency. Such high conversion efficiency enables us to pioneer an in situ cell reprogramming technology within the cancers of cancer-bearing animals. Instead of generating iPSCs in a dish, we perform cell reprogramming in vivo to convert cancer cells into piPSCs that immediately differentiate into non-cancerous cells inside tissues, allowing cancerous tissues to be repaired by normal cells. Using a subcutaneous cancer rat model, we demonstrated that this protein-induced pluripotency- based in situ cell reprogramming provided an effectivecell-converting therapy to cure subcutaneous glioma via the in situ conversion of malignant glioma cells into iPSCs for differentiation into non- cancerous cells under the differentiation tissue environment. We applied our QQ-protein delivery techniq

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government